GLP-1 family
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · N Engl J Med · 2022
PMID: 35658024 · DOI: 10.1056/NEJMoa2206038
Summary
Phase 3 randomized, double-blind, placebo-controlled trial (SURMOUNT-1) of once-weekly tirzepatide 5/10/15 mg vs placebo over 72 weeks in 2539 adults with obesity without diabetes. Primary endpoint: percent change in body weight.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →GLP-2 TDual-receptor incretin class agonist studied in metabolic-pathway research.
Guides covering this compound
More GLP-1 family citations
- Once-Weekly Semaglutide in Adults with Overweight or ObesityN Engl J Med · 2021
- Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)Lancet · 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3)JAMA · 2021